Chorulon 1500iu 5 pack

The active ingredient of Chorulon, human Chorionic Gonadotrophin (hCG), is a complex glycoprotein with luteinising hormone (LH) activity. In the female hCG can be used to promote maturation of the follicle, ovulation and the formation of the corpus luteum. In the male hCG stimulates the production of testosterone, and thus influences the development and maintenance of primary and secondary male sex characteristics

Legal Category POM-V

Dosage & Administration

Reconstitute with the solvent provided, ensuring the freeze-dried plug is fully dissolved. Administer by intramuscular or intravenous injection, observing the usual aseptic precautions.

Cow and heifer:

Repeated failure of conception: 1500 IU - i.m. or i.v. at AI or mating.

Cystic ovarian disease (anoestrus, prolonged oestrus, nymphomania): 3000 IU - i.v.

Enhancement of luteal function: 1500 IU i.m. 12 days after insemination or mating.

Mare:

Suboestrus (follicles > 2 cm in diameter): 1500 – 3000 IU - i.m. or i.v., repeat after 2 days if necessary.

Induction of ovulation: 1500 – 3000 IU - i.m. or i.v 24 hours before AI or mating.

Bitch:

Anoestrus: 500 IU - i.m. or i.v. at first day of oestrus after pre-treatment with PMSG 20 IU/kg s.c. daily for 10 days.

Delayed ovulation, prolonged pro-oestrus: 100 - 800 IU/day - i.m, repeating treatment until vaginal bleeding disappears. Mate on behavioural oestrus.

Male dog:

Deficiency in libido: 100 -500 IU - i.m. twice weekly for up to 6 weeks, but if this is not possible then 100 – 500 IU i.m. 6-12 hours before mating may give a temporary effect.

Further information

The product has been used in cases of cryptorchidism in the dog prior to castration (100-500 IU i.m. twice weekly for up to 6 weeks). Treatment may be effective in some cases provided that the inguinal canal is patent, and that therapy commences early.

The product has intrinsic LH-like activity. Injection of 1500 IU 12 days after heat in cattle enhances the active life of the corpus luteum by 2 to 3 days, resulting in increased progesterone and suppression of oestradiol production. These changes are consistent with those observed after GnRH use at day 11-13 of the cycle which are believed to be responsible for the increased pregnancy rates seen after such use. The mode of action is however different, since the product does not rely on first stimulating an endogenous LH peak. This use of the product has not been investigated in the field.